Jonathan Allan Sells 2,292 Shares of Stoke Therapeutics (NASDAQ:STOK) Stock

Stoke Therapeutics, Inc. (NASDAQ:STOK) General Counsel Jonathan Allan sold 2,292 shares of the business’s stock in a transaction on Wednesday, December 3rd. The shares were sold at an average price of $30.65, for a total transaction of $70,249.80. Following the completion of the sale, the general counsel owned 19,612 shares in the company, valued at $601,107.80. This represents a 10.46% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Jonathan Allan also recently made the following trade(s):

• On Tuesday, December 2nd, Jonathan Allan sold 2,284 shares of Stoke Therapeutics stock. The shares were sold at an average price of $29.78, for a total transaction of $68,017.52.
• On Friday, October 3rd, Jonathan Allan sold 10,000 shares of Stoke Therapeutics stock. The stock was sold at an average price of $25.07, for a total transaction of $250,700.00.

Stoke Therapeutics Trading Up 0.3%

NASDAQ:STOK opened at $31.05 on Friday. The stock has a market capitalization of $1.77 billion, a P/E ratio of 46.34 and a beta of 1.14. Stoke Therapeutics, Inc. has a 1 year low of $5.35 and a 1 year high of $38.69. The firm has a 50 day moving average of $28.90 and a 200-day moving average of $19.69.

Stoke Therapeutics (NASDAQ:STOK) last released its quarterly earnings results on Tuesday, November 4th. The company reported ($0.65) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.54) by ($0.11). The business had revenue of $10.63 million for the quarter, compared to analyst estimates of $6.06 million. Stoke Therapeutics had a net margin of 19.73% and a return on equity of 13.28%. As a group, analysts forecast that Stoke Therapeutics, Inc. will post -2.01 EPS for the current fiscal year.

Hedge Funds Weigh In On Stoke Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of STOK. Vanguard Group Inc. raised its holdings in Stoke Therapeutics by 7.4% during the 3rd quarter. Vanguard Group Inc. now owns 3,163,874 shares of the company’s stock worth $74,351,000 after buying an additional 217,616 shares during the period. Marshall Wace LLP increased its position in shares of Stoke Therapeutics by 7.9% during the second quarter. Marshall Wace LLP now owns 2,300,554 shares of the company’s stock worth $26,111,000 after acquiring an additional 168,771 shares in the last quarter. Siren L.L.C. raised its holdings in shares of Stoke Therapeutics by 12.4% during the first quarter. Siren L.L.C. now owns 2,247,347 shares of the company’s stock worth $14,945,000 after acquiring an additional 247,347 shares during the period. Goldman Sachs Group Inc. lifted its position in Stoke Therapeutics by 21.4% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,662,039 shares of the company’s stock valued at $11,053,000 after acquiring an additional 293,072 shares in the last quarter. Finally, Polar Capital Holdings Plc boosted its stake in Stoke Therapeutics by 49.8% in the 3rd quarter. Polar Capital Holdings Plc now owns 1,323,470 shares of the company’s stock worth $31,102,000 after purchasing an additional 439,824 shares during the period.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on STOK. Needham & Company LLC upped their price target on shares of Stoke Therapeutics from $22.00 to $35.00 and gave the stock a “buy” rating in a research report on Friday, October 10th. JPMorgan Chase & Co. upped their target price on shares of Stoke Therapeutics from $15.00 to $25.00 and gave the stock a “neutral” rating in a research report on Monday, November 3rd. BTIG Research reissued a “buy” rating and issued a $39.00 price target on shares of Stoke Therapeutics in a report on Wednesday, November 5th. Canaccord Genuity Group increased their price objective on Stoke Therapeutics from $24.00 to $28.00 and gave the company a “buy” rating in a research report on Wednesday, November 5th. Finally, Chardan Capital upgraded Stoke Therapeutics to a “strong-buy” rating in a research report on Wednesday, November 19th. Two equities research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $31.00.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.